MXPA05006399A - Metodos y formas de dosificacion para reducir los ataques al corazon en un individuo hipertenso con un diuretico o una combinacion de un diuretico y un inhibidor de la eca. - Google Patents

Metodos y formas de dosificacion para reducir los ataques al corazon en un individuo hipertenso con un diuretico o una combinacion de un diuretico y un inhibidor de la eca.

Info

Publication number
MXPA05006399A
MXPA05006399A MXPA05006399A MXPA05006399A MXPA05006399A MX PA05006399 A MXPA05006399 A MX PA05006399A MX PA05006399 A MXPA05006399 A MX PA05006399A MX PA05006399 A MXPA05006399 A MX PA05006399A MX PA05006399 A MXPA05006399 A MX PA05006399A
Authority
MX
Mexico
Prior art keywords
diuretic
dosage forms
heart attacks
methods
ace inhibitor
Prior art date
Application number
MXPA05006399A
Other languages
English (en)
Inventor
Raymond J Lipicky
Original Assignee
King Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Inc filed Critical King Pharmaceuticals Inc
Publication of MXPA05006399A publication Critical patent/MXPA05006399A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a metodos y formas de dosificacion para reducir y/o prevenir la incidencia de enfermedad cardiovascular, incluyendo ataques al corazon, en individuos en riesgo, tales como los individuos que padecen de hipertension. Los tratamientos y formas de dosificacion de la presente invencion se refieren a la administracion de un diuretico, como por ejemplo un diuretico de tiazida como Thalitone(r), ya sea solo en combinacion con un inhibidor de la ECA, como por ejemplo ramiprilo o ramiprilato como Altace(r), para reducir y/o prevenir la incidencia de enfermedad cardiovascular, especificamente ataques al corazon o insuficiente cardiaca en individuos que padecen de hipertension o estan en riesgo.
MXPA05006399A 2002-12-16 2003-12-16 Metodos y formas de dosificacion para reducir los ataques al corazon en un individuo hipertenso con un diuretico o una combinacion de un diuretico y un inhibidor de la eca. MXPA05006399A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43384502P 2002-12-16 2002-12-16
PCT/US2003/041056 WO2004056360A1 (en) 2002-12-16 2003-12-16 Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination

Publications (1)

Publication Number Publication Date
MXPA05006399A true MXPA05006399A (es) 2006-01-27

Family

ID=32681973

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006399A MXPA05006399A (es) 2002-12-16 2003-12-16 Metodos y formas de dosificacion para reducir los ataques al corazon en un individuo hipertenso con un diuretico o una combinacion de un diuretico y un inhibidor de la eca.

Country Status (10)

Country Link
EP (1) EP1589965A1 (es)
JP (1) JP2006511567A (es)
KR (1) KR20050102080A (es)
CN (1) CN1731996A (es)
AU (1) AU2003303208A1 (es)
BR (1) BR0317326A (es)
CA (1) CA2508269A1 (es)
IL (1) IL169148A0 (es)
MX (1) MXPA05006399A (es)
WO (1) WO2004056360A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536975A1 (en) 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
EP1734931A2 (en) 2004-03-24 2006-12-27 Actavis Group Formulations of ramipril
JP2008531579A (ja) 2005-02-24 2008-08-14 ニトロメッド インコーポレーティッド 酸化窒素増強利尿化合物、組成物および使用方法
US9769354B2 (en) 2005-03-24 2017-09-19 Kofax, Inc. Systems and methods of processing scanned data
US9767354B2 (en) 2009-02-10 2017-09-19 Kofax, Inc. Global geographic information retrieval, validation, and normalization
US9576272B2 (en) 2009-02-10 2017-02-21 Kofax, Inc. Systems, methods and computer program products for determining document validity
US9165187B2 (en) 2012-01-12 2015-10-20 Kofax, Inc. Systems and methods for mobile image capture and processing
US10146795B2 (en) 2012-01-12 2018-12-04 Kofax, Inc. Systems and methods for mobile image capture and processing
US9355312B2 (en) 2013-03-13 2016-05-31 Kofax, Inc. Systems and methods for classifying objects in digital images captured using mobile devices
US9208536B2 (en) 2013-09-27 2015-12-08 Kofax, Inc. Systems and methods for three dimensional geometric reconstruction of captured image data
US9311531B2 (en) 2013-03-13 2016-04-12 Kofax, Inc. Systems and methods for classifying objects in digital images captured using mobile devices
US20140316841A1 (en) 2013-04-23 2014-10-23 Kofax, Inc. Location-based workflows and services
DE202014011407U1 (de) 2013-05-03 2020-04-20 Kofax, Inc. Systeme zum Erkennen und Klassifizieren von Objekten in durch Mobilgeräte aufgenommenen Videos
US9386235B2 (en) 2013-11-15 2016-07-05 Kofax, Inc. Systems and methods for generating composite images of long documents using mobile video data
US9760788B2 (en) 2014-10-30 2017-09-12 Kofax, Inc. Mobile document detection and orientation based on reference object characteristics
US10242285B2 (en) 2015-07-20 2019-03-26 Kofax, Inc. Iterative recognition-guided thresholding and data extraction
US9779296B1 (en) 2016-04-01 2017-10-03 Kofax, Inc. Content-based detection and three dimensional geometric reconstruction of objects in image and video data
US10803350B2 (en) 2017-11-30 2020-10-13 Kofax, Inc. Object detection and image cropping using a multi-detector approach
CN109524075A (zh) * 2018-10-22 2019-03-26 平安医疗健康管理股份有限公司 基于数据处理的药品费用超标风险控制方法及装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3055904A (en) * 1957-11-04 1962-09-25 Geigy Chem Corp New isoindoline derivatives
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CN1731996A (zh) 2006-02-08
KR20050102080A (ko) 2005-10-25
CA2508269A1 (en) 2004-07-08
JP2006511567A (ja) 2006-04-06
AU2003303208A1 (en) 2004-07-14
EP1589965A1 (en) 2005-11-02
BR0317326A (pt) 2005-11-16
WO2004056360A1 (en) 2004-07-08
IL169148A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
MXPA05006399A (es) Metodos y formas de dosificacion para reducir los ataques al corazon en un individuo hipertenso con un diuretico o una combinacion de un diuretico y un inhibidor de la eca.
UA88265C2 (ru) Применение ингибитора ренин-ангиотензиновой системы для профилактики диабета
EP1059100A3 (en) Combinations of CRF antagonists and renin-angiotensin system inhibitors
McGill et al. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
WO2000027380A3 (en) Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
WO2005107747A3 (en) Diindolymethane formulations for the treatment of leiomyomas
NO20024921L (no) Kombinasjon av organiske forbindelser
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
WO2002043807A3 (en) Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
TW200637546A (en) Combination therapy
Lee Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria
Mangoni et al. The implications of a growing evidence base for drug use in elderly patients Part 2− ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients
EP0910375A4 (en) COMPOSITION BASED ON ENALAPRIL AND LOSARTAN
Mimran et al. Angiotensin‐receptor blockers and diuretics—Advantages of combination
WO1999043308A3 (en) Treating pulmonary hypertension through tenascin suppression and elastase inhibition
WO2003032963A3 (en) Method of reducing type 2 diabetes in high risk patients
Ahola Antihypertensive Drug Therapy in Finland-Utilization of Antihypertensive Medication, Control of Blood Pressure and Achievable Reduction of Cardiovascular Morbidity with intensified treatment
EE200400069A (et) Tsitalopraami kasutamine ravimkoostiste valmistamiseks kõrgenenud vererõhu raviks
PL1919483T3 (pl) Preparat złożony z diuretyku pętlowego i diuretyku tiazydowego
Rastogi et al. Reducing cardiorenal risk through combination therapy with a direct renin inhibitor
Beevers et al. Why are thiazide diuretics declining in popularity?
EP1611886A3 (en) Inhibitors of the renin-angiotensin system for the prevention of cardiovascular disorders
Gradman Treating Patients for Cardiovascular Protection: Combination Therapy to Achieve Complete Renin‐Angiotensin System Blockade
UA38773U (ru) Способ лечения больных артериальной гипертензией с синдромом инсулинорезистентности
Munter et al. Interaction of the renin-angiotensin-and the endothelin-system and its effect on blood pressure

Legal Events

Date Code Title Description
FA Abandonment or withdrawal